

Article

Not peer-reviewed version

PGmatrix 3D Shape Peptide Hydrogel for Sustained Release of Recombinant Human Bone Morphogenetic Protein-2 In Vitro

[Dalín Wang](#) , [Guangyan Qi](#) , [Mingcai Zhang](#) , Brandon Carlson , [Matthew Gernon](#) , Douglas Burton ,
[Xiuzhi Susan Sun](#) * , [Jinxi Wang](#) *

Posted Date: 17 October 2024

doi: 10.20944/preprints202410.1366.v1

Keywords: peptide hydrogel; PGmatrix; bone morphogenetic protein; drug delivery; controlled release; biomaterials



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

PGmatrix 3D Shape Peptide Hydrogel for Sustained Release of Recombinant Human Bone Morphogenetic Protein-2 In Vitro

Dalin Wang ¹, Guangyan Qi ², Mingcai Zhang ¹, Brandon Carlson ¹, Matthew Gernon ¹, Douglas Burton ¹, Xiuzhi Susan Sun ^{2,*} and Jinxi Wang ^{1,*}

¹ Department of Orthopedic Surgery, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA

² Department of Biological and Agricultural Engineering, Kansas State University, Seaton Hall, 919 Mid-Campus Drive North, Manhattan, KS 66506, USA

* Correspondence: xss@ksu.edu (X.S.S.); jwang@kumc.edu (J.W.); Tel.: +1-785-477-3392 (X.S.S.); +1-913-588-0870 (J.W.)

Abstract: The widespread clinical application of collagen sponge-delivered recombinant human bone morphogenetic protein-2 (rhBMP-2) for spinal fusion currently remains limited. This limitation is due to potential adverse events associated with the rapid release of excessively high doses. This study aimed to investigate the impact of varying PGmatrix 3D Shape peptide hydrogel (PepGel) formulations on the release kinetics of rhBMP-2 in vitro. Three PepGel formulations were assessed: 1) 50% v/v PepGel, where solution A (crosslinking reagent) was mixed with solution B (synthetic peptides) and rhBMP-2 solution, making a 50% v/v (solution B volume/total volume) PepGel; 2) 67% v/v PepGel; 3) 80% v/v PepGel. Each sample was loaded with 12 µg of rhBMP-2 and incubated in PBS. The incubation solution containing released rhBMP-2 was collected at 1 hour, 6 hours, and 1, 2, 4, 7, 10, 14, and 21 days, and released rhBMP-2 was quantified using a BMP-2 ELISA kit. To explore how PepGel formulations influence rhBMP-2 release, the gel porosities, swelling ratios, and mechanical properties of the three PepGel formulations were quantitatively analyzed. The results showed that rhBMP-2 encapsulated with 50% v/v PepGel exhibited a sustained release over the 21-day experiment. Between days 7 and 21, the 50% v/v PepGel demonstrated significantly higher rhBMP-2 release rates compared to the 67% and 80% v/v formulations. Higher histological porosity of PepGel was significantly correlated with increased rhBMP-2 release rates. Conversely, the swelling ratio and elastic modulus at 1.0 Hz of the 50% v/v PepGel was significantly lower than that of the 67% and 80% v/v formulations. In conclusion, this study indicates that varying the formulation of crosslinked PepGel can control rhBMP-2 release rates in vitro by modulating gel porosity, swelling ratio, and mechanical properties. Encapsulation with 50% v/v PepGel offers a sustained rhBMP-2 release pattern, which could mitigate the adverse effects associated with burst release of rhBMP-2 if replicated in vivo.

Keywords: peptide hydrogel; PGmatrix; bone morphogenetic protein; drug delivery; controlled release; biomaterials

1. Introduction

Spinal fusion is a common surgical procedure for patients with degenerative disc disease, scoliosis, or traumatic instability. This procedure aims to eliminate painful intervertebral segment motion by using rigid instrumentation and bone grafts to achieve a solid fusion, either posterolateral or interbody [1]. However, non-union (pseudoarthrosis) occurs in up to 35% of single-level spinal fusion procedures [2–4]. This complication can lead to poor outcomes with pain, revision surgery, and substantial socioeconomic burden. For decades, recombinant human bone morphogenetic

protein-2 (rhBMP-2) delivered with absorbable collagen sponge (ACS) has been used to improve spinal fusion rates. The mechanism of bone formation induced by rhBMP-2 and the host response to rhBMP-2 has been extensively studied [5–7].

However, clinical studies have documented adverse events of rhBMP-2 application in spinal fusion, including local hematoma formation and inflammation, radiculitis, and heterotopic ossification with or without neurologic impairment [8–12]. Research into the mechanisms behind these adverse events has shown that rhBMP-2 can trigger the release of proinflammatory cytokines, such as tumor necrosis factor- α (TNF- α), interleukin-1 α (IL-1 α), IL-1 β , and IL-6 in vitro. Animal models of spinal fusion have shown that the upregulated expression of proinflammatory cytokines at the fusion site peaks at 1 and 6 hours after applying a standard supraphysiological dose of rhBMP-2 delivered with ACS [6]. Furthermore, rhBMP-2 has been shown to promote osteoclastogenesis during osteoblastic differentiation [13] and upregulate osteoclast activity and bone resorption in a dose-dependent manner [14–17]. These findings suggest that the early burst release of supraphysiological doses of rhBMP-2 from ACS contributes to the adverse effects, hindering its widespread clinical use [18–22].

As a result, growing interest has been directed towards identifying suitable carriers for the controlled release of rhBMP-2 to enhance the osteogenic effects while minimizing adverse events [23–26]. A variety of biomaterials have been investigated for delivering therapeutic agents and cells in tissue engineering and disease treatment [27–32]. Among them, peptide hydrogels have gained recognition due to their unique, biocompatibility, and extracellular matrix (ECM)-like microenvironment [27,32–38].

Hydrogels also offer advantages in terms of injectability, homogeneous gel distribution, moldability, and better adaptability to defect margins. However, the use of injectable peptide hydrogel for delivering osteogenic factors in spinal fusion has not been reported, although peptide hydrogels have been used as scaffolds to deliver proteins in open bone repair procedures [39–41]. Moreover, the in vitro release kinetics of rhBMP-2 from hydrogels and the optimal release profile for locally delivered rhBMP-2 with distinct concentrations remained unknown. Therefore, further research is needed to determine whether varying peptide hydrogel formulations, such as gel concentration and network density (e.g., pore size and mesh size), can modulate drug release behavior. Identifying an optimal release profile for rhBMP-2 encapsulated in a specific peptide hydrogel concentration could help inform therapeutic strategies to reduce adverse events associated with the early-phase burst release of supraphysiological dosages of rhBMP-2.

The objective of this study was to investigate whether and how varying the formulation of a specific hydrogel, PGmatrix 3D Shape peptide hydrogel, could achieve a slow and sustained release of rhBMP-2 in vitro.

2. Materials and Methods

2.1. Composition of PGmatrix 3D Shape Peptide Hydrogel (PepGel)

A modified PepGel PGmatrix-CDX kit (PepGel LLC, Manhattan, KS) was provided by Dr. X.S. Sun in the Department of Biological and Agricultural Engineering, Kansas State University (Manhattan, KS). It contains PG matrix solution A (crosslinking trigger reagent, including minerals, ions, and water) and a modified PGmatrix CDX solution B (PGmatrix-3D-Shape, synthetic peptides based solubilized base membrane).

2.2. Encapsulation of rhBMP-2 in PepGels

To assess the effect of PepGel encapsulation on rhBMP-2 release in vitro, rhBMP-2 (CHO-expressed, R&D System, Catalog #355-GMP-050, Minneapolis, MN) was mixed with PepGel to create three formulations: 1) 50% v/v PepGel, in which 600 μ l PGmatrix solution B was added into 570 μ l rhBMP-2 solution (containing 12 μ g of rhBMP-2) and triggered with 30 μ l solution A. The ratio of solution A to solution B is fixed at 5%. The 50% v/v (volume/volume) concentration of PepGel is defined as the ratio of Solution B to the total volume of the mixture, and the formulation was assigned

as experimental testing. 2) 67% v/v (solution B volume/total volume) PepGel. 3) 80% v/v (solution B volume/total volume) PepGel (Table 1). Each sample from the three groups was loaded with 12μg of rhBMP-2, placed in sealed glass vials, and incubated at room temperature for 12 hours to allow for the complete PepGel formation.

Table 1. Three PepGel formulations for encapsulation of rhBMP-2.

Group	Solution A (ul)	12ug BMP in water (ul)	Solution B (ul)	Total volume (ul)*	Solution B/Total volume
I	30	570	600	1200	50% v/v
II	40	360	800	1200	67% v/v
III	48	192	960	1200	80% v/v

*Total volume per PepGel-rhBMP-2 sample.

2.3. *In Vitro* rhBMP-2 Release from PepGel

The mixture of PepGel-rhBMP-2 was stored in sealed glass vials and soaked in 18 mL phosphate buffered saline (PBS, Cytiva Life Science, Logan, UT) at pH 7.4 and incubated at 37 °C for a period of time as designed for supernatant collection. The incubation solution (supernatant) was collected and replenished with PBS at 1-hour (1hr), 6hr, and 1, 2, 4, 7, 10, 14, and 21 days. The amount of rhBMP-2 released from the PepGel was determined using a human BMP-2 ELISA kit (EHBMP2, Thermo Fisher Scientific, Waltham, MA) (Figure 1). The initial rhBMP-2 concentration was verified by using the standard curve with the same ELISA kit. Cumulative rhBMP-2 release was then calculated as a percentage of the initial loading amount.




Figure 1. A schema of rhBMP-2 encapsulation with PepGel and in vitro release assessment.

2.4. *Histological Analysis of PepGel Porosity*

PepGel samples were placed in PBS, processed through dehydration and paraffin infiltration, embedded in paraffin, and then sectioned at 5-micron on a rotary microtome. Sections were mounted on microscope slides. After deparaffinization and rehydration, the samples were stained with hematoxylin for 1 min, washed with 4-5 changes of Tap water, washed in 3 changes of distilled water, counterstained in alcoholic-eosin for 30 seconds, dehydrated through 80% EtOH and 100% EtOH, cleared in Xylene, and cover slipped with an acrylic-based mounting medium.

To evaluate the morphological difference in gel porosity among the three PepGel formulations, histological images were acquired using bright-field microscopy (Nikon Microsystems, Inc, Tokyo, Japan). Five tissue slides were assessed per sample. The porosity and Feret’s diameter of pores were measured using ImageJ software version 1.45s (<https://imagej.nih.gov/ij/>, U.S. National Institutes of Health, Bethesda, MD), and the average pore values from each sample were used for statistical analysis. Porosity represented the void spaces within the PepGel, calculated as a fraction of the volume of voids over the total volume, and expressed as a percentage of the total area. Feret’s diameter is a measure of pore size along a specified direction, defined as the distance between two parallel planes that restrict the object perpendicular to that direction [42].

2.5. Gel Swelling Analysis

Since the crosslink density and mesh size of the polymer network are highly associated with the extent of swelling [43], the swelling capacity of PegGel was assessed as follows [44,45]: First, the compound of PegGel-rhBMP-2 was prepared and gelatinated according to the protocol described in Table1. The gel was then soaked in PBS at pH7.4. After 1, 2, 4, 6, 8, 12, or 24hrs as designed, the supernatant was carefully removed, and the PegGel was weighed in its swollen condition to get the swollen weight (W_s). Finally, after lyophilization at -80°C and 4 mbar vacuum overnight to get the dry weight (W_d). All measurements were performed in triplicate, and the average values were used. The swelling parameters of PegGel at equilibrium were calculated using the following two equations [45]:

$$\text{Swelling ratio} = \frac{W_s - W_d}{W_d} \quad \text{Equilibrium water content (EWC)}(\%) = \frac{W_s - W_d}{W_s}$$

2.6. Dynamic Mechanical Property Testing

The rheological properties of PegGel (PGmatrix 3D Shape) were measured on a Kinexus lab + rheometer (Netzsch Instruments North America LLC, Burlington, MA, USA) with a 20-mm diameter parallel plate geometry and a 500-μm gap size. PegGels with the concentrations of 50, 67, and 80 v/v % were prepared as previously described.

Viscosity: Viscosity of each formulation of PegGel solution (without trigger solution A) was tested in the shear rate range of 0.01 to 10 s^{-1} under temperature of 25°C .

Shear modulus: The mixture of PegGel with trigger solutions A and DMEM basal medium was thoroughly mixed and placed on the rheometer's measuring plate. It was then incubated at 37°C for 30 minutes to facilitate hydrogel formation. Then a frequency sweep from 0.01 to 10 Hz was performed at a fixed strain of 1% to obtain the storage modulus (G') and loss modulus (G''). Additionally, a strain sweep ranging from 0.01% to 20% was conducted at a fixed frequency of 1 Hz to generate the stress-strain curve. The strain at which the hydrogel broke was recorded for each formulation.

Sol-gel reversible behaviors: The elastic modulus (G') of the PegGel hydrogel mixture with trigger solution A was continuously measured for 0 to 20 minutes at a hydrogel formation rate of 1 Hz and 1% steady shear strain to ensure a complete gel formation. Then the formed hydrogel was disrupted by applying a 500% shear strain for 2 minutes, after which the elastic modulus was monitored for an additional 15 minutes at 1 Hz and 1% shear strain to assess hydrogel sol-gel reversible behavior (self-recovery). A thin layer of silicone oil was applied around the sample's circumference to prevent dehydration.

2.7. Statistical Analysis

Statistical analyses of rhBMP-2 release kinetics, gel porosity, swelling data, and Pearson correlation coefficient analysis were performed using GraphPad Prism 9.1.1 (GraphPad, La Jolla, CA) or JMP Pro 17. The difference between means from two groups was analyzed by Student's t test (two tailed); the difference between means from three or more groups was determined by one-way ANOVA, followed by Tukey's or Dunnett's multiple comparison tests. The gel strength and recovery rate of the PegGel hydrogel were analyzed using repeated measures ANOVA (Analysis of Variance). All data are presented as means $\pm$ standard error of the mean (SEM). A p -value of less than 0.05 was considered statistically significant.

3. Results

rhBMP-2 release pattern: The rhBMP-2 capsulation with diverse formulations of PepGel resulted in significantly different release patterns during the 21-day experiment (Figure 2A). From 1hr to 4 days, the cumulative rhBMP-2 release rate of the 80% v/v PepGel was significantly lower than the 50% and 67% v/v PepGels. From 7 to 21 days, the rhBMP-2 release rate of the 50% v/v PepGel was significantly higher than the 67% and 80% v/v groups at each timepoint. From 4 to 21 days, the rh BMP release rates of 67% and 80% v/v PepGel groups essentially reached a plateau, whereas the release rates of the 50% v/v PepGel continuously rose till 14 days (Figure 2C-D). At day 21, the total cumulative rates of rhBMP-2 released from 50%, 67% and 80% v/v PepGels were $78.19 \pm 15.25\%$, $50.20 \pm 13.04\%$ and $19.14 \pm 7.79\%$ %, respectively.




Figure 2. (A) In vitro rhBMP-2 cumulative release kinetics from three different formulations of PepGel. (B) Comparison of rhBMP-2 cumulative release rates among the three groups at 1hr, 6hr, 1d. (C) Comparison of rhBMP-2 cumulative release rates among the three groups at 2d, 4d, 7d. (D) Comparison of rhBMP-2 cumulative release rate among three groups at 10d, 14d, 21d. *, ** and *** indicate significant differences with $p < 0.05$, $p < 0.01$ and $p < 0.001$, respectively. h = hour, d = day.

Gel porosity: The gel porosity was associated with the concentration of the PepGel formulations. Feret's diameter of 50%v/v PepGel ($2,135 \pm 16.67\text{nm}$) was significantly greater than 67% v/v PepGel ($1226 \pm 15.58\text{nm}$, $p < 0.01$) and 80% v/v PepGel ($1178 \pm 6.72\text{nm}$, $p < 0.01$). The porosity of the PepGel was significantly greater with 50%v/v PepGel ($61.13\% \pm 2.79$) compared to 67% v/v ($36.72\% \pm 3.29$, $p < 0.0001$) and 80% v/v ($29.85 \pm 3.04\%$, $p < 0.0001$) PepGels (Figure 3A-D). The porosity of 67% v/v PepGel was significantly greater than 80% v/v PepGel ($p < 0.001$). Higher rhBMP-2 release rates were positively correlated with higher gel porosities from day 1 to day 21 (Figure 4).




Figure 3. (A) Microscopic Images (x100) of PGmatrix 3D Shape Nanoweb Network. (B) Microscopic images (x400) magnified from the box in (A) (x400) (C) Microscopic images (x400) processed by ImageJ (D) ImageJ analysis of the pore size of the three PpGel groups. Hematoxylin and Eosin Staining; *, ** and *** indicate significant differences with $p<0.05$, $p<0.01$ and $p<0.001$, respectively.




Figure 4. Correlation analyses of gel porosity and cumulative rhBMP-2 release rate at each timepoint.

Gel swelling ratio: From 1 to 24 hrs, the swelling ratio of the 80% v/v PepGel was significantly higher than that of the 67% v/v ($p<0.01$) and 50% v/v ($p<0.001$) PepGels at each timepoint. At 24 hours, the swollen weight (Ws) of 67% v/v PepGel was 57.46 ± 20.20 folds compared to its dry weight (Wd),

and swelling ratio of 67% v/v PepGel was significantly higher than that of the 50% v/v PepGel (19.77 ± 6.18 , $p < 0.01$) (Figure 5A). From 2 to 24 hours, equilibrium water content (EWC) of the 50%V/V PepGel was significantly lower than that of the 67% v/v ($p < 0.05$) and 80% v/v ($p < 0.01$) PepGels at each timepoint (Figure 5B). The swelling ratio and equilibrium water content (EWC) were negatively correlated with gel porosities (Figure 6A-B).




Figure 5. (A) Comparison of the swelling ratio among three groups. (B) Comparison of the Equilibrium Water Content (EWC) among three groups. h = hour, n = 6 per PepGel formulation/timepoint. # $p < 0.05$, 80% V/V PepGel compared to 50% v/v PepGel * $p < 0.05$, 80% V/V PepGel compared to 67% v/v PepGel & $p < 0.05$, 50% V/V PepGel compared to 67% v/v PepGel.




Figure 6. (A) Correlation analysis of porosity and swelling ratio. (B) Correlation analysis of porosity and Equilibrium Water Content (EWC).

Dynamic mechanical properties: The mechanical properties of the PepGel PGmatrix 3D Shape were investigated with rheometry to reveal its viscoelasticity and gelation behaviors. PepGel exhibited a shear-thinning behavior, where the viscosity decreased more rapidly at shear rates below 1 1/s, before stabilizing as the shear rate increased to 10 1/s (Figure 7A). The elastic modulus (G') was found to depend on the concentration of PepGel (Figure 7B), with higher concentrations leading to a corresponding increase in the storage modulus of the hydrogel. Specifically, the elastic moduli (G') at 1.0 Hz for hydrogels with PepGel concentration of 50% v/v were significantly lower than that of 67% and 80% v/v PepGels (Figure 7C, Supplementary Table 1). The loss modulus (G'') also increased with concentration, though the differences were less pronounced (Figure 7D). The gel structure was characterized by the ratio of elastic modulus to loss modulus (G'/G''), with $G'/G'' = 1$ marking the critical point of gelation. The G'/G'' ratios for hydrogels at all concentrations exceeded 1.0 at 1.0 Hz (Figure 7D), indicating a stable gel structure. Hydrogels with PepGel concentrations of 50%, 67%, and 80% v/v showed relatively high G'/G'' values (6.9, 6.3, and 5.8, respectively). These gels exhibited

self-supporting properties but behaved as injectable liquids under small shear forces, such as those applied via a syringe. Noteworthy, the self-supporting PepGels at all concentrations exhibited rapid sol-gel reversible behavior (self-recovery) within a short time (Figure 7E). PepGel PGmatrix 3D Shape also demonstrated unique viscoelastic properties upon breakage. The elastic modulus required to break the gel increased with concentrations ranging from 50% to 80% v/v (Figure 7F), while the elongation at break remained consistently around 10% for all three hydrogels (Figure 7G). Gel strength (elastic moduli) was positively correlated with EWC but was negatively correlated with gel porosity (Figure 8A-B).




Figure 7. In vitro dynamic mechanical properties of PepGel formulations. (A) Viscosity and shear rate of PepGel solution (without trigger solution in each formulation). (B) Distribution of storage modulus (G') and loss modulus (G'') across the three PepGel formulations. (C) Elastic modulus across the three groups. (D) Comparison of the storage modulus (G') to loss modulus (G'') ratio for each PepGel group. (E) Fast reversible viscoelastic properties of PGmatrix 3D Shape peptide hydrogel. (F) Stress-strain curve and (G) strain at break for PepGel in each group. * Indicates $p < 0.05$, ns: no significance, $n = 3$.




Figure 8. (A) Correlation analysis of gel strength and EWC. (B) Correlation analysis of gel strength and gel porosity.

4. Discussion

This study presents a strategy for modulating rhBMP-2 release in vitro by varying the formulations of PGmatrix 3D Shape peptide hydrogel (PepGel) to achieve a sustained release of encapsulated rhBMP-2 that was in 50% v/v PepGel. Previous work by Olthof et al. measured the release of radiolabeled ^{125}I -rhBMP-2 delivered with ACS in vitro, reporting a total of 93.3% accumulative release within 3 days [24]. In contrast, the current study demonstrated that all three formulations of the PepGel exhibited lower release rates (about 60% or less of accumulative release) within 4 days. This slower release could reduce the BMP-2 burst-related inflammatory response at spinal fusion sites as the expression of local proinflammatory cytokines tends to peak at 1 and 6 hours [6]. Notably, the 50% v/v PepGel maintained sustained release over the 21-day experiment, while the higher concentrations of PepGel (67% v/v and 80% v/v) exhibited limited or no release of rhBMP-2 after 2 days. Although undesirable for sustained release in vitro, these higher concentration formulations could be beneficial for a long-term slow release in vivo in the presence of tissue-degrading enzymes.

This study explored possible mechanisms underlying the different release profiles of rhBMP-2 from the three PepGel formulations. First, porosity analysis of the self-assembled peptide nanofiber networks revealed significant differences among the three groups (Figure 3). Higher gel porosity was positively correlated with higher rhBMP-2 release rates from day 1 to day 21 (Figure 4). This correlation likely explains the premature release inhibition observed at higher concentrations of PepGel groups (67% v/v and 80% v/v). Second, the noncovalent crosslink density may increase with increased PepGel concentration [46], thus, varying the PepGel concentrations may alter the crosslink density and gel mesh size, thereby modulating rhBMP-2 release. Further studies are needed to address whether high crosslink density at high gel concentrations could compromise the injectability of PepGel. Third, our data revealed that the elastic modulus of the 50% v/v PepGel was significantly lower than that of the 67% v/v and 80% v/v formulations, and that Gel strength (elastic modulus) was negatively correlated with gel porosity (Figure 8), suggesting that elastic modulus of the PepGel might affect rhBMP-2 release. Further studies are required to confirm this potential mechanism.

The PepGel swelling ratio may also impact the exchange of nutrient proteins like rhBMP-2 within the ECM-like gel environment [45]. Hydrogels can absorb up to 1000 times their dry weight in liquid without undergoing dissolution [47]. In this study, PepGels with higher concentrations demonstrated a higher swelling ratio and EWC, likely due to increased water absorption. Swelling properties are generally influenced by factors like crosslink density, polymer composition, surrounding pH, ionic strength, temperature, gel concentration, and mechanical properties, etc. [48,49]. In this study, hydrogel concentration, crosslink density, and mechanical properties may have influenced the swelling behavior, but other factors, such as nanofiber structure and osmotic pressure

in the PepGel, could also be involved. Further research is needed to clarify the precise role of gel swelling in rhBMP-2 release.

Despite the increased elastic modulus with higher gel concentrations, PGmatrix 3D Shape displayed consistent shear-thinning and fast sol-gel reversible properties of across all three formulations. These unique rheological properties make PepGel suitable for injection-based delivery of encapsulated rhBMP-2 or other osteogenic biologics. Since injectable delivery of therapeutics can promote tissue healing, reduce infection risk, and support quick recovery, PepGel shows promise for in vivo minimally invasive spinal fusion procedures in animal models and potentially in human patients.

A limitation of this study is that the rhBMP-2 release patterns and material property evaluations were conducted in vitro without in vivo experiments. While PBS solution mimics the in vivo condition, it does not replicate the full complexity of the in vivo environment, which includes cellular components, proteins, enzymes, and a variety of ions. Therefore, in vivo studies are needed to validate the rhBMP-2 release profile for spinal fusion and other bone healing applications.

In conclusion, this study provides experimental evidence that varying the network density of PepGel can achieve controllable rhBMP-2 release kinetics. PepGel concentrations can be easily modulated to optimize sustained rhBMP-2 release for specific conditions. The 50% v/v PepGel appears to be a promising carrier for sustained releases of rhBMP-2 in vitro, while the 67% v/v formulation could be modified for long-term slow release in vivo in the presence of degradative enzymes. The unique shear-thinning and fast self-healing properties of PGmatrix 3D Shape make it a viable option for injectable delivery in minimally invasive spinal fusion studies. The in vitro results from this study warrant future investigations on in vivo release patterns and tissue response to PepGel-delivered rhBMP-2 at a bone healing or fusion site.

Author Contributions: Study design: JW, DW, and XSS. Methodology and data acquisition: DW, GQ, MZ, JW, and XSS. Data analysis and interpretation: DW, GQ, JW, XSS, MZ, BC, MG, and DB. Drafting and reviewing manuscript: DW, JW, XSS, GQ, MZ, BC, and MG. DW, JW, XSS, and GQ take responsibility for the integrity of the data analysis.

Acknowledgments: The work performed at the University of Kansas Medical Center was supported in part by the National Institute of Dental & Craniofacial Research of the National Institute of Health (NIH) under Award Number R01 DE018713 (to J.W.) and the Mary and Paul Harrington Distinguished Professorship Endowment. The work performed at Kansas State University was supported by Kansas State University and PepGel, LLC.

Data Availability Statement: The data presented in this study are available upon request from the corresponding authors.

Conflicts of Interest: The authors declare that they have no conflicts of interest.

References

1. Meng B, Bunch J, Burton D, Wang J. Lumbar interbody fusion: recent advances in surgical techniques and bone healing strategies. *Eur Spine J*. Jan 2021;30(1):22-33. doi:10.1007/s00586-020-06596-0
2. Yassen M, Li X, Jiang L, Yuan W, Che W, Dong J. Effect of zoledronic acid on spinal fusion outcomes in an ovariectomized rat model of osteoporosis. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*. Sep 2015;33(9):1297-304. doi:10.1002/jor.22763
3. Boden SD. The biology of posterolateral lumbar spinal fusion. *The Orthopedic clinics of North America*. Oct 1998;29(4):603-19.
4. Liu J, Tang J, Liu H. Comparison of one versus two cages in lumbar interbody fusion for degenerative lumbar spinal disease: a meta-analysis. *Orthopaedic surgery*. Aug 2014;6(3):236-43. doi:10.1111/os.12119
5. Hsu WK, Polavarapu M, Riaz R, et al. Characterizing the host response to rhBMP-2 in a rat spinal arthrodesis model. *Spine (Phila Pa 1976)*. May 20 2013;38(12):E691-8. doi:10.1097/BRS.0b013e31828cb977
6. Koerner JD, Markova DZ, Schroeder GD, et al. The local cytokine and growth factor response to recombinant human bone morphogenetic protein-2 (rhBMP-2) after spinal fusion. *Spine J*. Aug 2018;18(8):1424-1433. doi:10.1016/j.spinee.2018.03.006
7. Lee KB, Taghavi CE, Song KJ, et al. Inflammatory characteristics of rhBMP-2 in vitro and in an in vivo rodent model. *Spine (Phila Pa 1976)*. Feb 1 2011;36(3):E149-54. doi:10.1097/BRS.0b013e3181f2d1ec

8. Muchow RD, Hsu WK, Anderson PA. Histopathologic inflammatory response induced by recombinant bone morphogenetic protein-2 causing radiculopathy after transforaminal lumbar interbody fusion. *Spine J.* Sep 2010;10(9):e1-6. doi:10.1016/j.spinee.2010.06.020
9. Vaidya R, Sethi A, Bartol S, Jacobson M, Coe C, Craig JG. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. *J Spinal Disord Tech.* Dec 2008;21(8):557-62. doi:10.1097/BSD.0b013e31815ea897
10. McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). *J Spinal Disord Tech.* Oct 2006;19(7):483-6. doi:10.1097/01.bsd.0000211231.83716.4b
11. Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). *Spine J.* Nov-Dec 2008;8(6):1011-8. doi:10.1016/j.spinee.2007.06.014
12. Brower RS, Vickroy NM. A case of psoas ossification from the use of BMP-2 for posterolateral fusion at L4-L5. *Spine (Phila Pa 1976).* Aug 15 2008;33(18):E653-5. doi:10.1097/BRS.0b013e31817c4f1c
13. Otsuka E, Notoya M, Hagiwara H. Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. *Calcif Tissue Int.* Jul 2003;73(1):72-7. doi:10.1007/s00223-002-1071-0
14. Kanatani M, Sugimoto T, Kaji H, et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. *J Bone Miner Res.* Nov 1995;10(11):1681-90. doi:10.1002/jbmr.5650101110
15. Miyaji H, Sugaya T, Kato K, Kawamura N, Tsuji H, Kawanami M. Dentin resorption and cementum-like tissue formation by bone morphogenetic protein application. *J Periodontal Res.* Aug 2006;41(4):311-5. doi:10.1111/j.1600-0765.2006.00878.x
16. Wildemann B, Kadow-Romacker A, Lubberstedt M, Raschke M, Haas NP, Schmidmaier G. Differences in the fusion and resorption activity of human osteoclasts after stimulation with different growth factors released from a polylactide carrier. *Calcif Tissue Int.* Jan 2005;76(1):50-5. doi:10.1007/s00223-004-0040-1
17. Toth JM, Boden SD, Burkus JK, Badura JM, Peckham SM, McKay WF. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. *Spine (Phila Pa 1976).* Mar 15 2009;34(6):539-50. doi:10.1097/BRS.0b013e3181952695
18. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. *Spine J.* Jun 2011;11(6):471-91. doi:10.1016/j.spinee.2011.04.023
19. James AW, LaChaud G, Shen J, et al. A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. *Tissue Eng Part B Rev.* Aug 2016;22(4):284-97. doi:10.1089/ten.TEB.2015.0357
20. Vukicevic S, Oppermann H, Verbanac D, et al. The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing. *Int Orthop.* Mar 2014;38(3):635-47. doi:10.1007/s00264-013-2201-1
21. Tumialan LM, Pan J, Rodts GE, Mummaneni PV. The safety and efficacy of anterior cervical discectomy and fusion with polyetheretherketone spacer and recombinant human bone morphogenetic protein-2: a review of 200 patients. *J Neurosurg Spine.* Jun 2008;8(6):529-35. doi:10.3171/SPI/2008/8/6/529
22. Dickerman RD, Reynolds AS, Morgan BC, Tompkins J, Cattorini J, Bennett M. rh-BMP-2 can be used safely in the cervical spine: dose and containment are the keys! *Spine J.* Jul-Aug 2007;7(4):508-9. doi:10.1016/j.spinee.2007.03.003
23. Tateiwa D, Nakagawa S, Tsukazaki H, et al. A novel BMP-2-loaded hydroxyapatite/beta-tricalcium phosphate microsphere/hydrogel composite for bone regeneration. *Sci Rep.* Aug 19 2021;11(1):16924. doi:10.1038/s41598-021-96484-4
24. Olthof MGL, Kempen DHR, Liu X, et al. Bone morphogenetic protein-2 release profile modulates bone formation in phosphorylated hydrogel. *J Tissue Eng Regen Med.* Jun 2018;12(6):1339-1351. doi:10.1002/term.2664
25. Seeherman HJ, Wilson CG, Vanderploeg EJ, et al. A BMP/Activin A Chimera Induces Posterolateral Spine Fusion in Nonhuman Primates at Lower Concentrations Than BMP-2. *J Bone Joint Surg Am.* Aug 18 2021;103(16):e64. doi:10.2106/jbjs.20.02036
26. Zhang X, Yu Q, Wang YA, Zhao J. Dose reduction of bone morphogenetic protein-2 for bone regeneration using a delivery system based on lyophilization with trehalose. *Int J Nanomedicine.* 2018;13:403-414. doi:10.2147/ijn.S150875
27. Falcone N, Ermis M, Tamay DG, et al. Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery. *Adv Healthc Mater.* Oct 2023;12(27):e2301096. doi:10.1002/adhm.202301096
28. Ermis M, Falcone N, Roberto de Barros N, et al. Tunable hybrid hydrogels with multicellular spheroids for modeling desmoplastic pancreatic cancer. *Bioact Mater.* Jul 2023;25:360-373. doi:10.1016/j.bioactmat.2023.02.005

29. Xu L, Anderson AL, Lu Q, Wang J. Role of fibrillar structure of collagenous carrier in bone sialoprotein-mediated matrix mineralization and osteoblast differentiation. *Biomaterials*. Feb 2007;28(4):750-61. doi:10.1016/j.biomaterials.2006.09.022
30. Wang Q, Wang J, Lu Q, Detamore MS, Berklund C. Injectable PLGA based colloidal gels for zero-order dexamethasone release in cranial defects. *Biomaterials*. Jun 2010;31(18):4980-6. doi:10.1016/j.biomaterials.2010.02.052
31. Basu S, Pacelli S, Feng Y, Lu Q, Wang J, Paul A. Harnessing the Noncovalent Interactions of DNA Backbone with 2D Silicate Nanodisks To Fabricate Injectable Therapeutic Hydrogels. *ACS Nano*. Oct 23 2018;12(10):9866-9880. doi:10.1021/acsnano.8b02434
32. Hamilton M, Wang J, Dhar P, Stehno-Bittel L. Controlled-Release Hydrogel Microspheres to Deliver Multipotent Stem Cells for Treatment of Knee Osteoarthritis. *Bioengineering (Basel)*. Nov 15 2023;10(11)doi:10.3390/bioengineering10111315
33. Marin D, Marchesan S. Self-Assembled Peptide Nanostructures for ECM Biomimicry. *Nanomaterials (Basel)*. Jun 22 2022;12(13)doi:10.3390/nano12132147
34. Altunbas A, Lee SJ, Rajasekaran SA, Schneider JP, Pochan DJ. Encapsulation of curcumin in self-assembling peptide hydrogels as injectable drug delivery vehicles. *Biomaterials*. Sep 2011;32(25):5906-14. doi:10.1016/j.biomaterials.2011.04.069
35. Huang H, Ding Y, Sun XS, Nguyen TA. Peptide hydrogelation and cell encapsulation for 3D culture of MCF-7 breast cancer cells. *PLoS One*. 2013;8(3):e59482. doi:10.1371/journal.pone.0059482
36. Liang J, Liu G, Wang J, Sun XS. Controlled release of BSA-linked cisplatin through a PepGel self-assembling peptide nanofiber hydrogel scaffold. *Amino Acids*. Dec 2017;49(12):2015-2021. doi:10.1007/s00726-017-2444-z
37. Binaymotlagh R, Chronopoulou L, Palocci C. Peptide-Based Hydrogels: Template Materials for Tissue Engineering. *J Funct Biomater*. Apr 19 2023;14(4)doi:10.3390/jfb14040233
38. Michaels J, Kaleva AI, Bateman L, Wakelam O, Stephens J. Application of the Self-Assembling Peptide Hydrogel RADA16 for Hemostasis during Tonsillectomy: A Feasibility Study. *J Funct Biomater*. Sep 18 2024;15(9)doi:10.3390/jfb15090271
39. Kretlow JD, Klouda L, Mikos AG. Injectable matrices and scaffolds for drug delivery in tissue engineering. *Adv Drug Deliv Rev*. May 30 2007;59(4-5):263-73. doi:10.1016/j.addr.2007.03.013
40. Kretlow JD, Young S, Klouda L, Wong M, Mikos AG. Injectable biomaterials for regenerating complex craniofacial tissues. *Adv Mater*. Sep 4 2009;21(32-33):3368-93. doi:10.1002/adma.200802009
41. Ikeno M, Hibi H, Kinoshita K, Hattori H, Ueda M. Effects of self-assembling peptide hydrogel scaffold on bone regeneration with recombinant human bone morphogenetic protein-2. *Int J Oral Maxillofac Implants*. Sep-Oct 2013;28(5):e283-9. doi:10.11607/jomi.te09
42. Merkus H. Particle Size Measurements: Fundamentals, Practice, Quality. Springer; 2009:15-.
43. Bertz A, Wohl-Bruhns S, Miethe S, et al. Encapsulation of proteins in hydrogel carrier systems for controlled drug delivery: influence of network structure and drug size on release rate. *J Biotechnol*. Jan 20 2013;163(2):243-9. doi:10.1016/j.jbiotec.2012.06.036
44. Verma V, Verma P, Kar S, Ray P, Ray AR. Fabrication of agar-gelatin hybrid scaffolds using a novel entrapment method for in vitro tissue engineering applications. *Biotechnol Bioeng*. Feb 1 2007;96(2):392-400. doi:10.1002/bit.21111
45. Qiang L, Fan M, Wang Y, et al. Injectable hydrogel loaded with bilayer microspheres to inhibit angiogenesis and promote cartilage regeneration for repairing growth plate injury. *Front Bioeng Biotechnol*. 2023;11:1181580. doi:10.3389/fbioe.2023.1181580
46. Holloway JL, Ma H, Rai R, Burdick JA. Modulating hydrogel crosslink density and degradation to control bone morphogenetic protein delivery and in vivo bone formation. *J Control Release*. Oct 10 2014;191:63-70. doi:10.1016/j.jconrel.2014.05.053
47. Balakrishnan B, Banerjee R. Biopolymer-based hydrogels for cartilage tissue engineering. *Chem Rev*. Aug 10 2011;111(8):4453-74. doi:10.1021/cr100123h
48. Mandal B, Ray SK. Swelling, diffusion, network parameters and adsorption properties of IPN hydrogel of chitosan and acrylic copolymer. *Mater Sci Eng C Mater Biol Appl*. Nov 2014;44:132-43. doi:10.1016/j.msec.2014.08.021
49. Lam J, Kim K, Lu S, et al. A factorial analysis of the combined effects of hydrogel fabrication parameters on the in vitro swelling and degradation of oligo(poly(ethylene glycol) fumarate) hydrogels. *J Biomed Mater Res A*. Oct 2014;102(10):3477-87. doi:10.1002/jbm.a.35015

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.